Kiora Pharmaceuticals Inc (KPRX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Kiora Pharmaceuticals Inc stock (KPRX) is currently trading at $2.04. Kiora Pharmaceuticals Inc PS ratio (Price-to-Sales) is 363.74. Analyst consensus price target for KPRX is $12.00. WallStSmart rates KPRX as Sell.
- KPRX PE ratio analysis and historical PE chart
- KPRX PS ratio (Price-to-Sales) history and trend
- KPRX intrinsic value — DCF, Graham Number, EPV models
- KPRX stock price prediction 2025 2026 2027 2028 2029 2030
- KPRX fair value vs current price
- KPRX insider transactions and insider buying
- Is KPRX undervalued or overvalued?
- Kiora Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- KPRX Piotroski F-Score and Altman Z-Score
- KPRX analyst price target and Smart Rating
Kiora Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Kiora Pharmaceuticals Inc (KPRX) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Kiora Pharmaceuticals Inc (KPRX) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
Kiora Pharmaceuticals Inc (KPRX) Areas to Watch (4)
Company is destroying shareholder value
Very expensive at 363.7x annual revenue
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Kiora Pharmaceuticals Inc (KPRX) Detailed Analysis Report
Overall Assessment
This company scores 20/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 1 register as strengths (avg 10.0/10) while 4 fall into concern territory (avg 2.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.34) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Market Cap. Some valuation metrics including Price/Sales (363.74) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -32.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -32.60% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
KPRX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
KPRX's Price-to-Sales ratio of 363.74x sits near its historical average of 339.27x (69th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 81% below its historical high of 1930.6x set in Oct 2022, and 80731% above its historical low of 0.45x in Dec 2025. Over the past 12 months, the PS ratio has expanded from ~0.7x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Kiora Pharmaceuticals Inc (KPRX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Kiora Pharmaceuticals Inc operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.02 indicates a conservative balance sheet with 6M in cash.
Free cash flow is -1M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Kiora Pharmaceuticals Inc.
Bottom Line
Kiora Pharmaceuticals Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Kiora Pharmaceuticals Inc(KPRX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Kiora Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for ocular diseases and neurodegenerative disorders. With a pipeline of novel drug candidates addressing significant unmet medical needs, Kiora leverages its specialized expertise in drug formulation and delivery systems to advance its clinical studies towards regulatory approval. The company’s commitment to enhancing patient outcomes, supported by robust research capabilities and strategic partnerships, positions it favorably within the biopharmaceutical landscape and makes it an attractive opportunity for institutional investors looking to invest in cutting-edge therapeutics.